New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:34 EDTABIOARCA Biopharma announces GENETIC-AF CTA accepted by Health Canada
ARCA biopharma announced that the company’s Clinical Trial Application for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in Q4. ARCA is evaluating Gencaro as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the U.S. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.
News For ABIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:33 EDTABIOARCA Biopharma receives FDA fast track designation for Gencaro AF development
ARCA biopharma announced that the U.S. Food and Drug Administration has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population. Gencaro is the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use